You may find more results for this query on our sister sites: 360Dx and Precision Oncology News.
BioIQ will offer Fulgent's next-generation sequencing-based coronavirus assay on its diagnostic testing platform.
The companies have agreed to combine their respective liquid handling platforms and analysis software for integrated sample-to-answer PCR workflows.
Under the non-exclusive partnership, Emedgene will integrate its genome interpretation application into Illumina's TruSight software suite.
The firm said it will use the financing for ongoing development of software and learning models.
The partnership will integrate Milaboratories' MiXCR software into Enpicom's ImmunoGenomix platform for immune repertoire sequencing.
The methods, both published in Nature Biotechnology this week, result in completely phased haplotypes, without the need for sequencing parental samples.
The deal builds on a non-exclusive partnership signed in January 2019 and PierianDx will now support three more Illumina cancer sequencing assays.
Genosity will combine its Integrated Genomic Toolkit with Israel-based Igentify's genetic counseling software, which both firms will comarket.
The firm's CLIA lab presented data at the virtual ASHG meeting showing how it validated WGS-based STR expansion analysis to diagnose rare disease.
The firms will market Roche's Kapa HyperExome whole-exome sequencing probes alongside Fabric's Enterprise bioinformatics and analysis platform.
Politico reports that the NYPD DNA database has grown since it announced it would be removing profiles from it.
Forbes reports that a structural biology lab at Oxford University studying the coronavirus was hacked.
Science reports that a Dutch research funding agency is combating a ransomware attack.
In Science this week: set of 64 haplotype assemblies from 32 individuals, and more.
